The complex and evolving story of T cell activation to AAV vector-encoded transgene products.
about
Targeted approaches to induce immune tolerance for Pompe disease therapyGene therapy on the moveAdvances in gene therapy for muscular dystrophiesPre-clinical efficacy and dosing of an AAV8 vector expressing human methylmalonyl-CoA mutase in a murine model of methylmalonic acidemia (MMA)Heart failure-inducible gene therapy targeting protein phosphatase 1 prevents progressive left ventricular remodelingTherapeutic response in feline sandhoff disease despite immunity to intracranial gene therapy.Glial promoter selectivity following AAV-delivery to the immature brain.Full-length dystrophin reconstitution with adeno-associated viral vectorsAnti-inflammatory loaded poly-lactic glycolic acid nanoparticle formulations to enhance myocardial gene transfer: an in-vitro assessment of a drug/gene combination therapeutic approach for direct injection.Development of operational immunologic tolerance with neonatal gene transfer in nonhuman primates: preliminary studies.The potential of adeno-associated viral vectors for gene delivery to muscle tissue.Delivery of human EV71 receptors by adeno-associated virus increases EV71 infection-induced local inflammation in adult mice.Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors.A needleless liquid jet injection delivery method for cardiac gene therapy: a comparative evaluation versus standard routes of delivery reveals enhanced therapeutic retention and cardiac specific gene expression.A dystrophic muscle broadens the contribution and activation of immune cells reacting to rAAV gene transfer.Recombinant AAV-directed gene therapy for type I glycogen storage diseases.Evaluation of adeno-associated viral vectors for liver-directed gene transfer in dogs.Intrinsic transgene immunogenicity gears CD8(+) T-cell priming after rAAV-mediated muscle gene transfer.Improved Immunological Tolerance Following Combination Therapy with CTLA-4/Ig and AAV-Mediated PD-L1/2 Muscle Gene Transfer.Adeno-associated virus activates an innate immune response in normal human cells but not in osteosarcoma cells.Preclinical evaluation of a clinical candidate AAV8 vector for ornithine transcarbamylase (OTC) deficiency reveals functional enzyme from each persisting vector genome.Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe diseaseGene therapy approaches for lysosomal storage disease: next-generation treatment.Genome editing for inborn errors of metabolism: advancing towards the clinic.Gene Therapy for Duchenne muscular dystrophy.Center for fetal monkey gene transfer for heart, lung, and blood diseases: an NHLBI resource for the gene therapy community.Liquid jet delivery method featuring S100A1 gene therapy in the rodent model following acute myocardial infarction.Oral-tolerization Prevents Immune Responses and Improves Transgene Persistence Following Gene Transfer Mediated by Adeno-associated Viral Vector.Oral vaccination with adeno-associated virus vectors expressing the Neu oncogene inhibits the growth of murine breast cancer.Adeno-associated virus-coated allografts: a novel approach for cranioplasty.Genetic Manipulation of Brown Fat Via Oral Administration of an Engineered Recombinant Adeno-associated Viral Serotype Vector.The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia.Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodiesA multifunctional AAV-CRISPR-Cas9 and its host response.Innate Immune Responses to AAV VectorsFoxp3(+) regulatory T cells, immune stimulation and host defence against infection.Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera®).Virus expression vectors.Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy.Lung gene therapy-How to capture illumination from the light already present in the tunnel.
P2860
Q26767363-7177822A-2CE2-4132-8FF1-874B3E98E157Q27007012-FB1156BA-2991-4561-828F-931CA4686500Q28073994-9E4926DA-3BBB-4C0A-A125-066620C6C0A1Q28276617-641F68D0-5063-45EC-AD4C-7F0A62DDE8C1Q28482901-B7BB0C19-34E9-4B19-96A5-3F37A3E89E53Q30541192-5BA8A404-7C61-486E-B4D9-EB057334FE4AQ31120301-5835B805-F096-4F94-870C-248B68BA8DD0Q33782799-C787C7A4-EBDA-465B-A6AB-407ADA2993E7Q33799315-5FF598DB-631D-46CC-8FDF-A9EE618E2D8EQ33832987-7BA8155E-AF82-4EEA-A691-CE410C2B005CQ33902499-EB632325-3EAE-430A-BA0C-0B30709375CAQ34177586-5F371055-854B-43BF-801E-E811EEEBEB66Q34566454-17560E13-A15B-436E-A3ED-278216D9C9AEQ34669335-59CC95DE-7F6F-46CA-90D7-126C97FE5BC5Q34814931-12514F0F-8763-4DC7-A17C-CEBFE667EAF5Q35078590-6655720A-DC6C-4A02-B001-E5BB3BECAA83Q35174932-B14F8946-83B4-453F-8A23-25D6CE6C0744Q35399100-F19EEC2B-DC9E-4693-A96D-363831579CE9Q35451204-45E26073-BE7E-4BA1-AE54-2BC911E92B0FQ35599302-11542FBC-0922-4014-89AA-CE70B6DCAC4CQ35726773-B069C361-B1C0-4C40-BAB3-F8EB744915F5Q35988683-F5E266DC-4DCE-465F-A6EC-12B8B87AA38CQ36147475-9D3422F8-C66F-4F1B-A12D-CD1F341BE814Q36290952-BE8A061B-E0A4-442B-9C53-4EDFB5F1E169Q36295934-F7A90A22-5149-42C7-BA3A-F13219E9E0F7Q36401337-8A86D830-4382-4E28-BDF3-5E2726C9CBC7Q36547398-09A826FE-5246-4A02-972D-7B5015A66CA9Q36582796-B5C9D329-0982-4C69-BE72-93C974D8856DQ36659250-E193265A-669C-47C7-AFCE-AA2B92B7942BQ36838524-49A2AA33-E981-4372-A76C-0D4C13E09818Q37043485-237B83C9-33E7-4504-9C16-A58F7CB47F98Q37503995-C5695090-72C3-420B-B3B3-82A19CFA8C9FQ37621530-76889F3C-0D66-476F-9BF1-1359975832ADQ37731772-52815690-1FA6-47CB-8AE2-2DF32D8394DAQ37939843-B9664A8D-27B6-4269-A40D-86604F9EB43AQ37972689-0573A74C-3109-41AB-9ACE-D974C0A039A4Q38168940-5032656F-D8CE-451B-A560-57776124FC92Q38226671-7C6029AF-B1B1-496E-9AC3-AA6DE86B8F40Q38287263-4089B304-7216-4DAC-8A49-943FAF65A407Q38544793-4333BCFC-56DB-423B-98A2-72B01D7D9C67
P2860
The complex and evolving story of T cell activation to AAV vector-encoded transgene products.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
The complex and evolving story ...... or-encoded transgene products.
@en
The complex and evolving story ...... or-encoded transgene products.
@nl
type
label
The complex and evolving story ...... or-encoded transgene products.
@en
The complex and evolving story ...... or-encoded transgene products.
@nl
prefLabel
The complex and evolving story ...... or-encoded transgene products.
@en
The complex and evolving story ...... or-encoded transgene products.
@nl
P2860
P356
P1433
P1476
The complex and evolving story ...... or-encoded transgene products.
@en
P2093
James M Wilson
Lauren E Mays
P2860
P356
10.1038/MT.2010.250
P577
2010-11-30T00:00:00Z